Results 91 to 100 of about 5,801,283 (182)
Background Vitamin K deficiency impairs the activation of calcification inhibitors such as matrix Gla protein, promoting vascular calcification in CKD.
Irem Pamuk +11 more
doaj +1 more source
다중반응검지법을 이용한 AFP, AFP-L3, PIVKA-II 의 임상 정량법 개발과 분석적 검증 [PDF]
학위논문(박사)--서울대학교 대학원 :의과대학 의과학과,2019. 8. 김영수.Introduction: Alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) protein induced by vitamin K absence or antagonist-II (PIVKA-II) are serum biomarkers for ...
Areum Sohn
core
Introduction and Objectives: Despite existing surveillance methods, the diagnosis of hepatocellular carcinoma (HCC) in at-risk populations often occurs in advanced stages of the disease and carries a worse prognosis. AFP and PIVKA-II are two of the tumor
Dayron Páez Suárez +5 more
doaj +1 more source
ABSTRACT Background The most promising serum biomarkers for hepatocellular carcinoma (HCC) patients include PIVKA-II, AFP, and AFP-L3. Nevertheless, the effectiveness of combining biomarkers is still up for debate. This meta-analysis aimed to evaluate the diagnostic accuracy of PIVKA-II+AFP and PIVKA-
Abdulrahman Ibn Awadh +5 more
openaire +1 more source
Plasma levels of pivka-II in patients with autoimmune hepatitis
Orientador: Gabriel HesselDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: A hepatite autoimune (HAI) e uma doença inflamatória do fígado de etiologia desconhecida.
Sundell, Michelle de Oliveira Torres, 1980-
core
Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence
Tissue PIVKA-II was examined in 32 hepatocellular carcinomas and 2 metastatic liver tumors using indirect immunofluorescence, and the results were compared with the size, histological grading and serum PIVKA-II level.
Ito, Toshio +4 more
core
A Clinical Study of the Usefulness of PIVKA-II for the Early Detection of Hepatocellular Carcinoma
A plasma concentration of PIVKA-II was measured in 19 patients with hepatocellular carcinoma (HCC), 44 with liver cirrhosis, 16 with chronic hepatitis, 11 with other benign liver diseases and 10 with other extrahepatic carcinoma.
山城, 章裕 +19 more
core
378. Clinical study of PIVKA-II
masakazu furukawa +4 more
openaire +4 more sources

